Current trials for frontline therapy of mantle cell lymphoma
Abstract Mantle cell lymphoma (MCL) is a rare and incurable subtype of non-Hodgkin’s lymphoma that generally affects older individuals. However, the use of high-dose therapy and autologous stem cell transplant has improved significantly the prognosis of this hematological malignancy, but at the cost...
Main Authors: | Raphael E. Steiner, Jorge Romaguera, Michael Wang |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-01-01
|
Series: | Journal of Hematology & Oncology |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13045-018-0556-x |
Similar Items
-
Mantle cell lymphoma and its management: where are we now?
by: Abdullah Ladha, et al.
Published: (2019-01-01) -
Mantle Cell Lymphoma: Are New Therapies Changing the Standard of Care?
by: Susmita Sharma, et al.
Published: (2018-12-01) -
Mantle cell lymphoma
by: V. I. Vorob’ev, et al.
Published: (2020-11-01) -
Smoldering mantle cell lymphoma
by: Haige Ye, et al.
Published: (2017-12-01) -
Relapsed Mantle Cell Lymphoma: Current Management, Recent Progress, and Future Directions
by: David A Bond, et al.
Published: (2021-03-01)